Panthera is now undertaking Phase II, III and IV vaccine trials on behalf of its pharma and CRO clients across its growing network of sites in the UK.

Panthera, which was founded by Dr Ian Smith, the founder of Synexus and Prof. John Lyon, previously a Global Vice President at Covance, will continue to undertake trials for conditions treated in primary care including cardiovascular disease, osteoarthritis, osteoporosis, diabetes, allergies and migraine.

CEO Stuart Young commented:

“We have been approached by several sponsors to run vaccine studies. Our very experienced team has a great deal of expertise in this area and with our increasing number of sites across the UK, we are well positioned to deliver both patients and healthy volunteers, who are at lower risk for COVID-19, for these trials.”

Panthera, which only launched in October last year, is continuing its planned expansion with an increase in its network of sites across the UK and discussions with partners on international expansion, and specialized services in neurology, oncology and NASH are in development.

Covid-19

The safety of clinical trial patients and staff is paramount and Panthera is working with its pharma and CRO clients to assess each trial to see if it needs to be suspended, delayed or if it can be continued in a way that is safe both for the clinicians and participants. Panthera is working with sponsors who need to press ahead with trials, particularly those trials involving patients in high-risk categories. Panthera already has remote patient visit protocols in place including using phone or video links. These links are also being used for monitoring and site inspections.

Because some of Panthera’s sites are stand-alone, Panthera is able to help on existing studies where enrolled patients can be moved - protocol permitting - from hospitals and GP practices which may be unsafe and challenging from a resource perspective, in the current environment.

With new sites coming on line Panthera can be very nimble and has the ability to adapt to the sponsor’s needs.

Panthera Biopartners – an Independent Site Management Organisation

Panthera Biopartners was founded by Dr Ian Smith, founder of Synexus, and Professor John Lyon, previously Global Vice President at Covance, in 2019. Panthera provides CROs and pharma clients with services relating to the recruitment and running of clinical trials at its own clinical trial sites managed by GCP trained healthcare professionals. Other members of the team include CCO, Jane Restorick, previously the global COO at Synexus and CEO Stuart Young, former MD of Synexus UK.

The first Panthera site was opened in Preston, Lancashire, UK in October 2019 and the second in North Manchester in March this year. Further sites are planned in Glasgow and North London with several sites under negotiation. Panthera initially focused on therapeutic areas traditionally managed in primary care but has continued to expand its offering to include vaccines.

https://panthera-bio.com/